Combining Alpelisib and Ribociclib for Colorectal Cancer Treatment
Author Information
Author(s): Aslam Razia, Richards Cathy E., Fay Joanna, Hudson Lance, Workman Julie, Lee Cha Len, Murphy Adrian, O’Neill Brian, Toomey Sinead, Hennessy Bryan T., Dricu Anica
Primary Institution: RCSI University of Medicine and Health Sciences
Hypothesis
Can the combination of Ribociclib and Alpelisib overcome drug resistance in colorectal cancer?
Conclusion
The combination of Alpelisib and Ribociclib shows a synergistic anti-tumor effect in colorectal cancer models, suggesting it could be a promising treatment strategy.
Supporting Evidence
- The combination therapy led to a significant reduction in tumor growth in xenograft models.
- Alpelisib and Ribociclib together reduced key proteins involved in cancer cell survival.
- The study demonstrated a synergistic effect across different colorectal cancer cell lines.
- Enhanced apoptosis markers were observed with the combination treatment.
Takeaway
This study found that using two cancer drugs together can work better than using them alone, helping to fight colorectal cancer more effectively.
Methodology
The study evaluated the effects of Alpelisib and Ribociclib on colorectal cancer cell lines and in vivo models, measuring cell viability, signaling pathway activation, and tumor growth.
Limitations
Only four cell lines were tested, and some important mutations were not included; also, the viability of chick embryos in the CAM model limited the study.
Statistical Information
P-Value
0.0004
Confidence Interval
95% CI = 0.4619 to 1.168
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website